Long-term Efficacy of Vedolizumab for Crohn’s Disease

Vermeire, Séverine; Loftus, Edward V.; Colombel, Jean–Frédéric; Feagan, Brian G.; Sandborn, William J.; Sands, Bruce E.; Danese, Silvio; D’Haens, Geert R.; Kaser, Arthur; Panaccione, Remo; Rubin, David T.; Shafran, Ira; McAuliffe, Megan; Kaviya, Arpeat; Sankoh, Serap; Mody, Reema; Abhyankar, Brihad; Smyth, Michael

doi:10.1093/ecco-jcc/jjw176

Cited by 139 publications

(196 citation statements)

References 20 publications

Supporting

Mentioning

174

Contrasting

Unclassified

Order By: Relevance

“…There is evidence for an exposure–efficacy relationship for vedolizumab induction therapy 2. Increasing dosing frequency of vedolizumab to every 4 weeks leads to an improvement in clinical response in both ulcerative colitis (UC)3 and Crohn’s disease (CD) 4. In contrast to anti-tumour necrosis factor (TNF) agents, the correlation between the response to dose optimisation and changes in the pharmacokinetic profile of vedolizumab-treated patients remains unknown.…”

mentioning

confidence: 99%

Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation

Gouynou

Pouillon²,

Rousseau

et al. 2018

Gut

View full text Add to dashboard Cite

mentioning

confidence: 99%

Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation

Gouynou

Pouillon²,

Rousseau

et al. 2018

Gut

View full text Add to dashboard Cite

“…Eighty-nine percent of the patients with Crohn's disease and 96% of the patients with ulcerative colitis who responded to vedolizumab induction therapy achieved clinical remission [5,6].…”

Section: Doi: 101159/000492322mentioning

confidence: 99%

“…Seven patients discontinued vedolizumab therapy due to lack of response before week 30 (median week 15, range [6][7][8][9][10][11][12][13][14][15][16][17][18][19]. Three of these underwent colectomy (2 at week 6 and 1 at week 15).…”

Section: Secondary Endpoints In Ulcerative Colitismentioning

confidence: 99%

Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn’s Disease at a Tertiary Referral Center

Hoffmann

Krisam

Stremmel

et al. 2018

Dig Dis

View full text Add to dashboard Cite

Background: Vedolizumab was approved for the therapy of ulcerative colitis and Crohn’s disease in mid-2014. Real-world treatment data are necessary for a balanced assessment of its position among other therapeutic options. Summary: Patients with ulcerative colitis or Crohn’s disease, initiating vedolizumab therapy at the outpatient clinic for inflammatory bowel diseases at the University Hospital Heidelberg between June 1, 2014 and August 31, 2016, were recruited based on electronic medical records. The primary study endpoint was response at week 30, while the secondary endpoints were the need for surgery and discontinuation of therapy due to inadequate response, or adverse events. Twenty-five patients with ulcerative colitis (40% anti-tumor necrosis factor α [TNFα] naive) and 28 patients with Crohn’s disease (10.7% anti-TNFα naive, 53.6% having undergone at least one intestinal surgery) were enrolled. Among the ulcerative colitis patients, 20% achieved remission, 32% partial response, and 48% were non-responders to vedolizumab. In Crohn’s disease, 14.3% of the patients achieved remission, 46.4% partial response, and 39.4% were non-responders. Two patients discontinued vedolizumab therapy due to suspected side effects. Key Message: In a relatively treatment-refractory cohort of inflammatory bowel disease patients, vedolizumab was efficacious in achieving response. However, the majority of the patients were not satisfactorily treated, as they did not reach remission.

show abstract

“…К 52-й неделе 36,4% паци-ентов, продолживших принимать ведолизумаб (каждые 4 недели), находились в состоянии клинической ремиссии по сравнению с 21,6% пациентов группы плацебо (p = 0,004) [65]. В дальнейшем 83% пациентов, ответивших на терапию ведолизумабом к 6-й неделе и продолжающих принимать препарат, оставались в состоянии ремиссии к 104-й неделе наблюдения [66]. Отдельно стоит отметить, что терапия ведолизумабом показала свою эффектив-ность у пациентов с ВЗК, рефрактерными к антиTNFα-терапии.…”

Section: инфликсимабunclassified

Targeted therapy of inflammatory bowel diseases: realities and prospects

Маев¹,

Андреев²

2018

Med. sov.

View full text Add to dashboard Cite

Long-term Efficacy of Vedolizumab for Crohn’s Disease

Cited by 139 publications

References 20 publications

Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation

Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation

Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn’s Disease at a Tertiary Referral Center

Targeted therapy of inflammatory bowel diseases: realities and prospects

Contact Info

Product

Resources

About